NCT06261489RecruitingPhase 2
Cannabis (THC vs. CBD) in Multiple Sclerosis
The Differential Effects of THC vs. CBD on Cognition in Persons With MS
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to examine the effect of Cannabis components, THC and CBD, on cognition and bladder symptoms in people with Multiple Sclerosis (MS). Participants will complete questionnaires and cognitive tests. They will be randomly assigned to receive either CBD or THC oil and will take the study drug for 15 weeks.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Jan 2024
- Start date
- 5 Dec 2025
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- University of Calgary
- Diseases
- Multiple sclerosis
- NCT number
- NCT06261489
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 30
- From 5 Dec 2025 to the primary completion date, 30 Sept 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of antipsychotic medication
- Currently using cannabis/CBM less than 3x/week and being unwilling to abstain for the duration of the study.
Other illness
- Major psychiatric disorder such as schizophrenia or bipolar disorder
- Major neurological disorder which could affect cognition such as dementia, traumatic brain injury.
- Seizure disorder
Other
- Use of benzodiazepines other than exclusively at night/bedtime
- Experienced a MS relapse in the last ninety (90) days.
- Current use of cannabis or CBM greater than 3x/week.
- Visual acuity (binocular) worse than 20/70 (in order to complete the cognitive outcomes)
- Significant upper extremity disability that would interfere with the cognitive tests battery.
- Indwelling catheter use/urinary diversion
- Pregnant or Breastfeeding
Who the study is looking for
- Age between 26 and 59 years inclusive.
- Confirmed diagnosis of Multiple Sclerosis as per McDonald criteria (any type) \[12\]
- Symptoms of neurogenic lower urinary tract dysfunction (NLUTD) as measured by neurogenic bladder symptom score (NBSS), with a minimum score of 7.
- If already on a medication for NLUTD, must be stable on this medication for at least 4 weeks.
- Sexually active men and women of child-bearing potential must agree to use adequate contraception.
- Written informed consent.
Age in the registry: 26 years to 59 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Calgary Foothills Medical Center Coordinator of this site? Confirm its status | Calgary | Canada | Recruiting |
| University Of Calgary Coordinator of this site? Confirm its status | Calgary | Canada | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.